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The p53 gene is a critical tumor suppressor that is inactivated in a
majority of cancers. The central role of p53 in response to stresses
such as DNA damage, hypoxia, and oncogene activation underlies
this high frequency of negative selection during tumorigenic trans-
formation. Mutations in p53 disrupt checkpoint responses to DNA
damage and result in the potential for destabilization of the
genome. Consistent with this, p53 mutant cells have been shown
to accumulate genomic alterations in cell culture, mouse models,
and some human tumors. The relationship between p53 mutation
and genomic instability in human osteosarcoma is addressed in this
report. Similar to some other primary human tumors, the mutation
of p53 correlates significantly with the presence of high levels of
genomic instability in osteosarcomas. Surprisingly, osteosarcomas
harboring an amplification of the HDM2 oncogene, which inhibits
the tumor-suppressive properties of p53, do not display high levels
of genomic instability. These results demonstrate that the inacti-
vation of p53 in osteosarcomas directly by mutation versus indi-
rectly by HDM2 amplification may have different cellular conse-
quences with respect to the stability of the genome.
The p53 protein is a critical tumor suppressor and centralmediator of cellular responses to stress. Inactivating muta-
tions of the p53 gene occur in 50% of all sporadic human
cancers (1–3). In addition, mutations in known p53-interacting
genes such as HDM2 and p14ARF bring the sum total of cancers
that display functional inactivation of the p53 pathway to 80%
(4–6). Highlighting the central role of p53 in tumor suppression
is the predisposition of individuals who inherit a mutated p53
allele to a variety of cancers at an early age including breast
carcinoma, soft-tissue sarcomas, brain tumors, osteosarcoma,
acute leukemias, and adrenocortical carcinoma (7). Similarly,
homozygous p53 knockout mice have a 100% chance of devel-
oping cancer (usually thymic lymphomas) before the age of 6
months, and heterozygous mice develop a variety of cancers at
a later age including osteosarcoma, soft-tissue sarcomas, and
lymphomas (8–11).
The p53 protein mediates responses to a variety of stresses
including DNA damage, oncogene activation or mutation, hyp-
oxia, depleted nucleotide pools, shortened telomeres, viral in-
fection, spindle damage, nitric oxide, etc. (12). In response to one
or more of these signals, p53 is posttranslationally stabilized and
activated as a transcription factor to turn on or off the expres-
sions of different sets of downstream target genes (13). The
collective functions of these p53 target genes serve to execute
various cellular programs that respond to stress by growth arrest,
apoptosis, senescence, or cell–cell signaling (14–16).
Consistent with a role in the response to DNA damage, p53
has been shown to inhibit gene amplifications and deletions,
which can be initiated by DNA double-strand breaks. Control
over DNA copy number by p53 was first demonstrated by using
antimetabolites that induce resistance by gene amplification in
cell culture (17, 18). p53 heterozygous (p53/) fibroblasts fail to
show phosphonoacetyl-L-aspartate-induced amplifications of
the CAD gene during culture until loss of heterozygosity (LOH)
for p53 (p53/), after which gene-amplification frequencies
increase by 500- to 1,000-fold.More recently it was demonstrated
that these primary human p53/ cell cultures also undergo
spontaneous chromosomal deletions after LOH for p53, as
detected by the comparative genome hybridization (CGH) tech-
nique, which detects large chromosomal gains and losses in the
entire genome (19). A number of reports have shown a similar
correlation between the mutational inactivation of p53 and
increased genomic instability in vivo. Gene amplifications are
common in cells from the normal (nontumor) tissues of the p53
knockout mouse and are detectable as early as 4–6 weeks of age
(20). Also, tumors arising in p53 heterozygous mice that undergo
LOH for p53 accumulate 5-fold more chromosomal aberrations
than tumors in which one wild-type p53 allele is retained (21). In
human tumors, mutations in the p53 gene have been shown to
correlate with genome-wide instability in colorectal carcinomas
(P  0.05) as defined by CGH (22), with an increase of
karyotypic abnormalities and chromosomal amplifications de-
tected by fluorescence in situ hybridization on four chromosomes
in breast carcinomas (P  0.008) (23), and with genome-wide
allelic imbalances detected by single-nucleotide polymorphism
array analysis in bladder cancer (24). Taken together, these data
suggest that the loss of p53 function contributes to tumorigenesis
by the destabilization of the genome.
Although the initial experiments describing a role for p53 in
surveillance of genomic integrity were performed with primary
human fibroblast cell cultures, human sarcomas, which also arise
from mesenchymal cells, have not been assayed for genomic
instability and p53 status in vivo. Sarcomas, including osteosar-
comas and several types of soft-tissue sarcomas, are induced by
the loss of p53 function in both heterozygous p53 knockout mice
(10, 11) and Li–Fraumeni cancer syndrome patients (7). Also,
the effects of mutations in direct p53-interacting genes on
genomic stability, such as amplifications of the HDM2 oncogene
that occur more frequently in sarcomas than in any other cancer
types, have never been examined. The Hdm2 oncoprotein, the
gene of which is a downstream transcriptional target of p53,
functions as a direct negative regulator of p53 protein function
and stability in an autoregulatory feedback loop (25). Whether
amplifications of the HDM2 oncogene, which have been dem-
onstrated to impair the tumor-suppressor functions of p53 (26)
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and occur predominantly in p53 wild-type tumors (27), have an
impact on genome stability that mimics that of mutations in p53
has not been established.
One human sarcoma that is ideally suited for analyses of
genomic instability is osteosarcoma. Osteosarcomas are themost
common malignant bone tumors in adults and children, with a
peak incidence during the second decade of life (28). High-grade
osteosarcomas are ideally suited for genomic-instability analyses
because, on average, these tumors contain as high or even higher
levels of genomic instability than almost any other cancer. By
CGH, these tumors have 9–11 independent chromosomal
lesions per tumor, as shown in several previous reports (29–31).
In addition to a high mean number of genomic changes, these
tumors also collectively display a broad spectrum of instability,
where some have20 chromosomal aberrations and others have
few or no detectable changes (30), and there is no known genetic
rationale for the difference between the two types.
In this report, the role of the p53 tumor-suppressor protein in
controlling the stability of the genome in primary high-grade
osteosarcomas is addressed. Genomic instability was assayed in
34 primary osteosarcomas by CGH, and the p53 pathway status
was determined by both p53 gene mutational screening and
genomic copy-number analysis of HDM2. Consistent with the
results found with other human cancers, the mutation of p53
significantly correlates with genome-wide DNA instability and
seems to represent a major genetic factor contributing to the
extremely high levels of genomic instability found in high-grade
osteosarcomas. Surprisingly, genomic amplification of the
HDM2 oncogene, which occurred independently of mutations in
p53, did not correlate with high levels of genomic instability in
these tumors. Osteosarcomas with amplified HDM2 displayed
less than half as many genomic copy-number alterations on
average than those with mutations in p53. These data demon-
strate a lack of genetic equivalency for HDM2 oncogene ampli-
fications and p53 tumor-suppressor gene mutations with respect
to the stability of the genome in uncultured human tumors.
Materials and Methods
Patients. Osteosarcoma tumor samples were collected from
patients who had surgery at Memorial Sloan–Kettering Cancer
Center between 1992 and 2000. All samples had a histologically
confirmed pathologic diagnosis of high-grade osteosarcoma. All
patients provided written informed consent for tissue procure-
ment. Tumors were procured in accordance with a biology study
approved by theMemorial Sloan–Kettering Institutional Review
Board. Patients from whom these samples came were treated on
or according to the pediatric intergroup phase III clinical trial
(CCG no. 7921) described previously. Genomic DNA was pre-
pared from the osteosarcoma patients samples by using a
QIAamp DNeasy tissue kit (Qiagen, Valencia, CA) according to
manufacturer instructions.
CGH. CGH was performed as described (32). Copy-number
changes were detected based on the variance of the redgreen
ratio profile from the standard of 1. Ratio values of 1.2 and 2.0
were defined as thresholds for gains and high-level amplifica-
tions, respectively, and losses were defined as a ratio value of
0.8.
p53 Genotyping. Single-strand conformation polymorphism and
DNA sequencing were performed essentially as described (33).
Primers to amplify p53 exons 5–8 were purchased from Sigma
Genosys (see Table 4, which is published as supporting infor-
mation on the PNAS web site, www.pnas.org). DNA sequencing
was performed by The Rockefeller University DNA Technology
Center.
Multiplex PCRligase-detection reaction for p53, linked to
read out on a universal DNA microarray, was performed as
described (34). This technique allows for the detection of 110
specific p53 missense mutations in exons 5–8.
TaqMan Real-Time Quantitative PCR.HDM2 gene copy number was
determined for each tumor relative to a control gene on chro-
mosome 21, APP. Primers and TaqMan probes used for ampli-
fication and detection of both HDM2 and APP genes were
purchased from Sigma Genosys (Table 4). PCR cycling condi-
tions were 95°C for 10 min and 40 cycles of 95°C for 15 sec, 55°C
for 30 sec, and 60°C for 30 sec, followed by one cycle of 60°C for
5 min. Reactions were performed by using the ABI 7700
sequence detector (TaqMan) from Applied Biosystems. Real-
time quantitative assays were performed essentially as described
(35). Briefly, standard curves were calculated for each gene by
10-fold serially diluting genomic DNA from normal placenta
(Sigma). HDM2 gene copy numbers were determined by using
the mean threshold cycle for each tumor, performed in triplicate,
to calculate copy number from the HDM2 standard curve. APP
control gene copy numbers were determined similarly from the
APP standard curve and used for normalization of HDM2.
Results are reported asHDM2 fold amplification relative toAPP.
Statistical Tests. The correlation of p53 status with genomic-
instability score was analyzed by using custom software written
in MATLAB 6.5 (Mathworks, Natick, MA). Mock CGH data sets
were generated under the null hypothesis of no correlation
between p53 mutations and level of instability. Each mock data
set was identical to the real set, i.e., contained the same number
of tumors and changes per tumor but with random assignments
of p53mutant (n 12) orHDM2-amplified (n 5) tumor status.
The mean number of chromosomal changes in p53 mutant and
HDM2-amplified tumors in each such data set was calculated.
The P value for the significance of the correlation of p53 status
with genomic instability in the real data set was defined as the
frequency of mock data sets that yielded a greater or equal mean
number of changes per tumor than that of the real set (19.1)
when 12 p53mutant tumors were assigned randomly. The P value
that expresses the significance of HDM2 amplification and its
correlation to low-level instability was calculated similarly as the
frequency of trials that yielded a mean number of changes that
was lower or equal to that of the real set (8.8) when five
HDM2-amplified tumors were assigned randomly. In both cases,
200,000 random data sets were generated.
Results
DNA Copy-Number Changes Identified by CGH.GenomicDNAs from
34 primary high-grade osteosarcoma tumors were subjected to
CGH analysis to identify chromosomal copy-number changes
relative to normal genomic DNA (Fig. 1 and Table 5, which is
published as supporting information on the PNAS web site).
Losses were detected on every autosome and the X chromosome
in at least one tumor with the exception of chromosome 21. The
most recurrent losses were of chromosomal regions 18q21q23 at
1434 tumors (41%), followed by 6q16 at 1334 tumors (38%)
and 10q22q26 at 1234 tumors (35%). Increases in copy number
were detected on every autosome and the X chromosome in at
least one tumor. The most frequently gained or amplified
chromosomal regions were 17p11.2 and 6p12 at 1634 (47%),
followed by 1p32p36 at 1534 (44%) and 8q24 at 1534 (44%).
Notably, 9 of the 16 tumors displaying increased copy number at
17p11.2, and 8 of 16 at 6p12, had high-level amplifications of
these regions, which represent approximately 5-fold increases
in copy number (36).
An instability score was assigned to each tumor, which is the
sum of all losses, gains, and high-level amplifications detected in
each sample (Fig. 2). Similar to a previous report of osteosar-
coma CGH (30), a wide spectrum of genomic instability was
found, with some tumors displaying few or no detectable changes
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and others displaying 20 chromosomal aberrations. The 34
tumors examined in this study include 21 tumor biopsies taken
before chemotherapy, 5 resections taken after chemotherapy, 4
recurrent tumors from relapsed patients, and 4 metastatic
tumors (Fig. 2).
p53 Mutational Screening. Thirty-two of the 34 osteosarcomas
were screened for mutations in the p53DNA-binding domain by
a combination of single-strand conformation polymorphism
sequencing and PCRligase-detection reactionmicroarray tech-
niques. The PCRligase-detection reaction technique is highly
sensitive and allowed for the detection of mutations that other-
wise were missed by single-strand conformation polymorphism
(Table 1). p53mutations were found in 12 of 32 tumors (38%),††
in exons 5–7, including three missense mutations at the com-
monly altered hotspot codons 175 and 273 (Table 1). Five other
missense mutations occurred at codons 272, 281, 220, 224, and
173. Each of these mutations has been described in a variety of
different cancers (37–42).
p53 mutant tumors were overrepresented among samples
displaying high levels of genomic instability (Fig. 3a). The mean
instability score for p53 mutant tumors was 19.1 chromosomal
changes per tumor as compared with 11.1 for all other tumors.
This correlation is statistically significant (P  0.004) (Fig. 3b).
The presence of mutant p53was also significantly correlated with
genomic instability in biopsy specimens (n 21), with a mean of
19.9 changes in seven p53 mutant tumors versus 9.7 for all other
biopsies (P  0.009) (Fig. 4).
HDM2 Real-Time Quantitative PCR. Genomic amplification of the
HDM2 gene was assayed by real-time quantitative PCR with
TaqMan fluorescent probes. Gene copy numbers for HDM2
were normalized against the APP gene from chromosome 21.
Amplification of this chromosome 21 locus has been shown to be
extremely rare in a panel of breast carcinomas at a frequency of
0108 (43). Also, in a previous CGH analysis of osteosarcomas,
chromosome 21 was the least-commonly altered out of all
chromosomes with one loss and two gains detected in total of 31
tumors (30). In the 34 osteosarcomas reported here, 5 of 34
osteosarcoma tumors were found to have 3-fold amplification
of the HDM2 gene over the chromosome 21 control (Fig. 5).
Three of these tumors had high-level amplifications of HDM2,
from 11- to 21-fold.
In contrast to p53 mutant tumors, osteosarcomas displaying
genomic amplification of HDM2 do not exhibit high levels of
genomic instability (Figs. 3a and 4). The mean number of
chromosomal aberrations for fiveHDM2-amplified tumors is 8.8.
In this set of osteosarcomas, HDM2 oncogene amplifications
actually cluster in the group of tumors with low levels of genomic
instability (four of the five HDM2-amplified tumors are in the
lower half of all tumors sorted by instability score) (Fig. 3a);
however, this correlation is not significant (P  0.1357).
††Several tumor samples were selected for this study based on the prior knowledge that
they stained positively for p53 by immunohistochemistry (data not shown).
Fig. 1. Ideogram of CGH-detectable copy-number changes in 34 osteosar-
coma tumors. Copy-number gains are depicted by thin gray lines to the right
of each chromosome, high-level amplifications (approximately 5-fold) are
depicted by thick gray bars, and losses are depicted by thin black lines to the
left of each chromosome.
Fig. 2. Genomic-instability scores. The instability score for each sample is the
total number of gains, losses, and high-level amplifications detectable by CGH.
The CGH data from 34 high-grade osteosarcoma tumors (Fig. 1 and Table 5) are
shown by sample type.
Table 1. p53 mutation screening
Tumor p53 mutation SSCP PCRLDR
1 OS2 Exon 8, D281H G3 C  
2 OS3 Exon 8, V272M G3 A  
3 OS6 Exon 5, R175H G3 A  
4 OS7 Exon 6, frameshift  NT
5 OS8 Exon 8, R273H G3 A  
6 OS11 Exon 5, frameshift, del 17nt  NT
7 OS17 Exon 6, E224D G3 C  NT
8 OS19 Exon 6, Y220C A3 G  NT
9 OS22 Exon 5, V173M G3 A  NT
10 OS27 Exon 5, deletion codon 190  NT
11 OS28 Exon 5, V173G T3 G  NT
12 OS31 Exon 8, R273C C3 T  
SSCP, single-strand conformation polymorphism; LDR, ligase-detection re-
action;, found by technique;, not found; NT, not tested; det 17nt, deletion
of 17 nucleotides.
Overholtzer et al. PNAS  September 30, 2003  vol. 100  no. 20  11549
G
EN
ET
IC
S
Discussion
In this study, 34 high-grade osteosarcomas were analyzed for
genome-wide chromosomal aberrations by CGH, and 32 of these
were assayed for p53 mutations and genomic amplification of
HDM2. The chromosomal abnormalities described in this set of
tumors are similar in nature to a previous report with roughly the
same number of high-grade osteosarcoma samples (n 31) (30).
A large number of genome alterations were detected, affecting
every autosome and the X chromosome in at least one tumor,
highlighting the breadth and magnitude of chromosomal insta-
bility in these tumors. There exists, above this genetic noise, a
subset of genomic alterations that appear reproducibly in both
studies (n  65) (Tables 2 and 3). Copy-number increases at
chromosomal regions 1q21, 8q24, 6p12, 8cenq13, 1p31p32, and
17p11.2 are the most significantly reproducible of 65 osteosar-
comas. These regions of the osteosarcoma genome are likely to
harbor genes that play a significant role in the initiation andor
propagation of tumorigenesis as evidenced by their repeated
amplification in uncultured tumors. Notably, in the CGH data
reported here, regions 17p11.2 and 6p12 seem to be highly
significant by both quantitative (47% and 44%) and qualitative
criteria, because each region is highly reproducible with a small
Fig. 3. p53mutation,HDM2 amplification, and genomic-instability score. (a)
Osteosarcoma tumors with genomic amplification of HDM2 or mutation of
p53 are depicted with corresponding genomic-instability scores. (b) P-value
determination for p53 status and genomic-instability score. The probability
distribution curve depicts the distribution of the mean numbers of genomic
changes of 12p53mutant tumors of 200,000 randomized trials. The filled area
underneath the curve (shown by the arrow) highlights those trials that pro-
duced a higher or equal mean number of changes to the actual mean (19.1).
Fig. 4. Instability scores for osteosarcoma tumor biopsies. p53 mutant and
HDM2-amplified osteosarcoma tumor biopsies are depicted with genomic-
instability scores.
Fig. 5. Real-time quantitative PCR analysis ofHDM2. The gene copy number
for HDM2 for each tumor is shown relative to APP. Error bars represent SD.
Table 2. CGH summary of 65 osteosarcomas
This report (34 tumors) Previous report* (31 tumors)
Locus No. of tumors (%) Locus No. of tumors (%)
Most frequent copy-number increases
6p12 1634 (47), 8† 1q21 1831 (58), 1
17p11.2 1634 (47), 9 8q21.3q22 1631 (52), 3
1p32p36 1534 (44) 8cen-q13 1431 (45), 2
8q24 1534 (44), 2 8q23q24 1331 (42), 1
20q 1134 (32), 1 14q24qter 1131 (35), 2
Xp21 1134 (32) Xp11.2p21 1131 (35), 4
8cen-q13 1034 (29), 1 5p14 1031 (32), 2
5p13-cen 1034 (29) 6p12p21.3 1031 (32), 3
1q21 1034 (29), 2 11q14 1031 (32)
17q21q25 734 (21), 1 1p32q21 931 (29), 2
Most frequent copy-number losses
18q21q23 1434 (41) 6q16 1031 (32)
6q16 1334 (38) 6q21q22 1031 (32)
10q22q26 1234 (35) 10q23qter 931 (29)
13q21q31 1134 (32) 10p12pter 931 (29)
10p 834 (24) 13q21 831 (26)
*Previous data are from Tarkkanen et al. (30).
†Bold numerals indicate the number of all copy-number increases that were
high-level amplifications.
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common region of overlap that often presents as a high-level
amplification (Fig. 1).
The significant correlation of p53 mutations with high levels of
genomic instability in these osteosarcomas (Figs. 3 and 4) is
consistent with experimental data obtained in cell culture (17, 18)
and data from other uncultured human tumors in which p53 has
been demonstrated to control the stability of the genome (22–24).
The mutation of p53 therefore may be one major genetic factor
contributing to the extremely high levels of genomic instability in
some high-grade osteosarcomas. These data support the hypothesis
that the loss of p53 function contributes to tumorigenesis by the
destabilization of the genome.
The inhibition of homologous recombination by wild-type p53
has been reported by a number of groups and is one potential
mechanism for control over the stability of the genome by p53
(44–48). Interestingly, a recent report examined the effective-
ness of various p53 mutants at inhibiting homologous recombi-
nation. A p53 protein with a mutated Arg-273 residue was the
most severely impaired for inhibition of homologous recombi-
nation, whereas a mutation disrupting Asp-281 performed more
similarly to wild-type p53 (48). In the present study, the Asp-281
mutant tumor had an instability score of 8, whereas two tumors
with mutations disrupting Arg-273 had approximately two to
three times more instability with scores of 15 and 23, suggesting
that the ability of specific mutations to inhibit homologous
recombination may correlate with the genomic-instability scores
determined by CGH.
Surprisingly, amplification of theHDM2 gene, which occurred
mutually exclusive of p53 mutations, did not correlate with high
levels of genomic instability in the osteosarcoma tumors re-
ported here. In fact, p53 mutant tumors displayed a genomic-
instability score that is more than twice that of the average
HDM2-amplified tumor. The Hdm2 oncoprotein functions as a
direct negative regulator of p53. Negative regulation by Hdm2 is
achieved by the (i) direct binding and blocking of the p53
transactivation domain (25, 49–51), (ii) Hdm2-mediated shut-
tling of p53 from the nucleus to the cytoplasm (52, 53), and (iii)
E3-ligase function of Hdm2, which targets p53 for ubiquitin-
mediated proteasomal degradation (54). Overexpression of
HDM2 by gene amplification has been observed in many differ-
ent cancers and has been demonstrated to inhibit p53-dependent
transactivation and apoptosis (26, 55). Amplification of HDM2
is therefore considered to effectively ‘‘knock out’’ or inactivate
p53 protein function and, in so doing, may constitute the genetic
equivalent to a p53 mutation. Consistent with this idea, the
mutation of p53 and amplifications of HDM2 are normally
mutually exclusive events in tumors with rare exception (27).
Because p53mutations and HDM2 amplifications were mutually
exclusive genetic events, it is tempting to hypothesize that,
although both events may achieve the inhibition of certain
p53-mediated functions, on some level the amplification of
HDM2 may not be equivalent to a p53 mutation with respect to
genomic instability. Recently it was reported that the inactiva-
tion of p53 by stable short hairpin RNA (shRNA)-mediated
silencing in mice mimics the p53 gene knockout phenotype and
contributes to tumorigenesis in the E-myc mouse lymphoma
model (56). Interestingly, different p53 shRNA constructs con-
tributed to tumorigenesis to varying degrees based on their
differing abilities to knockdown levels of p53 protein. Although
the loss of p53 by genetic knockout results in marked genomic
instability in this model, none of the tumors that developed as a
result of shRNA-mediated p53 knockdown, which retain residual
levels of p53 protein, displayed high levels of genomic instability.
These results and the data from human tumors presented here
suggest that reducing the levels of wild-type p53 protein, endog-
enously by HDM2 amplification or exogenously by RNA inter-
ference, may contribute to tumorigenesis by inhibiting some p53
functions while still allowing for the maintenance of a relatively
stable tumor genome by residual concentrations of p53. Further
experiments are required to determine whether other human
tumors with amplifications of HDM2 behave similarly and
maintain relatively stable genomes as compared with tumors
harboring a mutation in p53.
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